News
06-07-2010, 03:59 AM
Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.
More... (http://www.news-medical.net/news/20100607/Eisais-eribulin-mesylate-improves-median-OS-compared-with-TPC-in-pre-treated-metastatic-breast-cancer-patients.aspx)
More... (http://www.news-medical.net/news/20100607/Eisais-eribulin-mesylate-improves-median-OS-compared-with-TPC-in-pre-treated-metastatic-breast-cancer-patients.aspx)